Trial Profile
The retension rate and tolerability of fingolimod in relapsed remitting multiple sclerosis patients who switched from other oral DMTs
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 08 May 2017 New trial record
- 28 Apr 2017 Results (n=386) presented at the 69th Annual Meeting of the American Academy of Neurology